KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Free Cash Flow (2019 - 2025)

Royalty Pharma (RPRX) has disclosed Free Cash Flow for 7 consecutive years, with $93.5 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow fell 62.02% to $93.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $792.1 million through Dec 2025, up 200.85% year-over-year, with the annual reading at $792.1 million for FY2025, 200.85% up from the prior year.
  • Free Cash Flow hit $93.5 million in Q4 2025 for Royalty Pharma, up from -$259.3 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $595.0 million in Q1 2025 to a low of -$866.3 million in Q3 2021.
  • Historically, Free Cash Flow has averaged $107.8 million across 5 years, with a median of $282.2 million in 2021.
  • Biggest five-year swings in Free Cash Flow: soared 2467.27% in 2021 and later plummeted 501.15% in 2024.
  • Year by year, Free Cash Flow stood at $318.2 million in 2021, then rose by 0.46% to $319.7 million in 2022, then plummeted by 171.82% to -$229.6 million in 2023, then surged by 207.18% to $246.1 million in 2024, then plummeted by 62.02% to $93.5 million in 2025.
  • Business Quant data shows Free Cash Flow for RPRX at $93.5 million in Q4 2025, -$259.3 million in Q3 2025, and $362.9 million in Q2 2025.